NextCure, Inc. (NXTC)
6.39
+0.30
(+4.93%)
USD |
NASDAQ |
Aug 31, 16:00
6.26
-0.13
(-2.03%)
After-Hours: 07:22
NextCure Debt to Equity Ratio : 0.3529 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.3529 |
| March 31, 2026 | 0.1843 |
| December 31, 2025 | 0.1475 |
| September 30, 2025 | 0.2007 |
| June 30, 2025 | 0.1676 |
| March 31, 2025 | 0.1046 |
| December 31, 2024 | 0.0909 |
| September 30, 2024 | 0.075 |
| June 30, 2024 | 0.0721 |
| March 31, 2024 | 0.0669 |
| December 31, 2023 | 0.0577 |
| September 30, 2023 | 0.0506 |
| June 30, 2023 | 0.0493 |
| March 31, 2023 | 0.0469 |
| December 31, 2022 | 0.0425 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.01 |
| March 31, 2021 | 0.0109 |
| December 31, 2020 | 0.0118 |
| September 30, 2020 | 0.0127 |
| June 30, 2020 | 0.0134 |
| March 31, 2020 | 0.0142 |
| December 31, 2019 | 0.0156 |
| September 30, 2019 | 0.0293 |
| June 30, 2019 | 0.028 |
| March 31, 2019 | 0.0457 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 22.62M |
| Total Liabilities (Quarterly) | 10.47M |
| Shareholders Equity (Quarterly) | 12.15M |
| Current Ratio | 3.470 |
| Net Debt Paydown Yield | 4.78% |